Novartis plans to acquire Endocyte, a biopharmaceutical company, to accelerate the development of innovative radioligand technology for treating cancer in a deal worth $2.1 billion (EUR 1.8 billion). / read more /
advertisement
Subscribe
Subscribers can enjoy each full issue of Pharm Tech Europe in print, or via Pharm Tech Europe apps.
According to CPhI's annual report, the therapeutic antibody drug conjugates (ADC) market is expected to reach US$4 billion (approximately EUR 3 billion) by 2023. / read more /
Evonik sets new standard for enteric coatings:
EUDRAGIT® FL 30 D-55 is an advanced, new combination polymer solution for enteric coatings that integrates the respective benefits of two existing, well-accepted monographs. It is highly flexible, plasticizer-free, and can be sprayed with a smooth, fast and no-stick process. As a single product, preparation times can be reduced by up to 70%. Visit Evonik at AAPS (booth 2127) or email healthcare@evonik.com Learn more
The companies will work together to develop Ionis-FB-LRx for the treatment of complement-mediated diseases, including Geographic Atrophy (GA), the advanced stage of dry age-related macular degeneration (AMD), in a deal worth US$760 million (EU 664 million). / read more /
The companies will work together to advance a number of Morphic's oral integrin therapeutics for fibrosis-related indications in a deal with US$100 million (EUR 87 million). / read more /
The investment includes an upgrade and expansion of the company's packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy. / read more /
The contract development and manufacturing organization released its first serialized products to Europe from its facilities in Lisbon, Portugal and Stockholm, Sweden. / read more /
Internal release limits help ensure that a batch of drug product remains within specifications throughout its shelf life. This article explores what internal release limits are and why they are important. / read more /
This ebook covers novel technologies for the formulation, manufacture, purification, and delivery of sterile small- and large-molecule drugs, including single-use systems, facilities and equipment, contamination issues, and process analytics.
